1.39
Schlusskurs vom Vortag:
$1.93
Offen:
$1.79
24-Stunden-Volumen:
12.46M
Relative Volume:
6.12
Marktkapitalisierung:
$340.30M
Einnahmen:
$12.87M
Nettoeinkommen (Verlust:
$-114.34M
KGV:
-1.6077
EPS:
-0.8646
Netto-Cashflow:
$-79.23M
1W Leistung:
-16.27%
1M Leistung:
-13.13%
6M Leistung:
-30.85%
1J Leistung:
-51.57%
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
TSHA
Taysha Gene Therapies Inc
|
1.39 | 340.30M | 12.87M | -114.34M | -79.23M | -0.8646 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
2021-12-16 | Eingeleitet | Guggenheim | Buy |
2021-07-16 | Eingeleitet | Needham | Buy |
2021-06-24 | Eingeleitet | Truist | Buy |
2021-06-15 | Eingeleitet | BTIG Research | Buy |
2021-06-09 | Eingeleitet | Wedbush | Outperform |
2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
2021-05-11 | Fortgesetzt | Jefferies | Buy |
2021-02-24 | Eingeleitet | William Blair | Outperform |
2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
2020-10-19 | Eingeleitet | Goldman | Buy |
2020-10-19 | Eingeleitet | Jefferies | Buy |
2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com India
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment By Investing.com - Investing.com South Africa
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com Australia
Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan
TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks
Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Taysha Gene Therapies Reports 2024 Financial Results - TipRanks
Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability - TipRanks
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Taysha Gene Therapies reports FY24 EPS (36c) vs (96c) last year - TipRanks
Taysha Gene Therapies Inc Reports Full Year 2024 EPS of -$0.36 a - GuruFocus.com
Earnings call transcript: Taysha Gene's Q4 2024 reports narrower loss, stock dips - Investing.com
Earnings call transcript: Taysha Gene’s Q4 2024 reports narrower loss, stock dips - Investing.com India
Taysha Gene Therapies, Inc. SEC 10-K Report - TradingView
Can Taysha's Gene Therapy for Rett Syndrome Deliver? Key Safety Milestone Reached as Cash Extends to 2026 - StockTitan
Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday - Defense World
Taysha Gene Therapies to Release Full-Year 2024 Financial - GlobeNewswire
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - The Manila Times
Gene Therapy Pioneer Taysha Readies Crucial 2024 Financial DisclosureHere's When - StockTitan
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Brokerages - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by SG Americas Securities LLC - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3%Time to Buy? - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Taysha Gene Therapies Inc [TSHA] Records 50-Day SMA of $1.9835 - Knox Daily
Taysha's Strategic Move: 491K Stock Options Awarded to Secure Top Industry Talent - StockTitan
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Prepare Yourself for Liftoff: Taysha Gene Therapies Inc (TSHA) - SETE News
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):